









Markets
/
Stocks
/
nasdaq-xoma
/

XOMA Royalty Corp

XOMA

View Detailed Chart

26.740USD

-0.750-2.73%

Close 05/14, 16:00（ET）Quotes delayed by 15 min

319.61MMarket Cap

LossP/E TTM



XOMA Royalty Corp

26.740

-0.750-2.73%

Company

Intraday

30m

Today

-2.73%

5 Days

+9.23%

1 Month

+31.85%

6 Months

0.00%

Year to Date

0.00%

1 Year

0.00%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 4 analysts

BUY

Current Rating

64.667

Target Price

135.24%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

XOMA Royalty Corp

XOMA

Roku Inc

ROKU

Live Nation Entertainment Inc

LYV

Warner Music Group Corp

WMG

TKO Group Holdings Inc

TKO

Imax Corp

IMAX

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(0)

Neutral(2)

Buy(6)

Indicators

Sell(0)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

RSI(14)

STOCH(KDJ)(9,3,3)

ATR(14)

CCI(14)

Williams %R

TRIX(12,20)

StochRSI(14)

Moving Average

Sell(0)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

MA10

MA20

MA50

MA100

MA200

News

More news coming soon, stay tuned...

Company

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others.

Company codeXOMA

CompanyXOMA Royalty Corp

CEOMr. Owen P. Hughes, Jr.

Websitehttps://www.xoma.com/